Tarbox Family Office’s Coherus Oncology CHRS Stock Holding History

Tarbox Family Office’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-42	Closed	-$1K	–	1146
2020 Q3	$1K	Buy	+42	New	+$781	﹤0.01%	935

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Tarbox Family Office's CHRS Position: Q4 2020 in Review

Tarbox Family Office sold out of Coherus Oncology (CHRS) in Q4 2020, closing a stake of 42 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in CHRS in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 196 funds tracked by Wall St. Rank hold CHRS as of Q4 2020.

Tarbox Family Office reported no remaining Coherus Oncology position as of Q4 2020 after selling out during the quarter.
Tarbox Family Office sold 42 Coherus Oncology shares in Q4 2020, an estimated $1K.
Tarbox Family Office first reported a position in Coherus Oncology in Q3 2020 and held it in 1 quarter.
Tarbox Family Office's Coherus Oncology position peaked at $1K in Q3 2020.
196 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2020.

Based on Tarbox Family Office's 13F filing for Q4 2020, filed 27 Jan 2021.